secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-045123
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q3 net revenue $3.1M (down 63% YoY); net loss $6.6M ($0.35/sh)
----------------------------------------------------------------------------

- Net revenue $3.1M vs $8.4M in Q3 2023; net loss $6.6M ($0.35/sh) vs $5.1M ($0.30/sh).
- Pharmaloz Manufacturing hired ThinkEquity to explore sale; projects $15M+ revenue over next 12 months.
- BE-Smart esophageal cancer test initiated partnership talks with two billion-dollar diagnostic firms.
- Equivir trial completed; final stats expected by end-November; preliminary data encouraging.
- Cash $1.1M at Sep 30; plans to eliminate ~$6M/year overhead; working capital $13.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224045123/0001493152-24-045123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224045123/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer